Literature DB >> 28214549

ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.

Julie Dartier1, Elsa Lemaitre2, Igor Chourpa3, Caroline Goupille4, Stéphane Servais5, Stéphan Chevalier6, Karine Mahéo7, Jean-François Dumas8.   

Abstract

BACKGROUND: We hypothesized that, among the mechanisms of drug-resistance acquired by doxorubicin (DOX)-resistant breast cancer cells to maintain cell survival, ATP-dependent drug efflux pumps could be expressed in their mitochondrial membranes and this might limit the accumulation of DOX in this subcellular compartment in relation to mitochondrial ATP production. METHODS/
RESULTS: Mitochondrial DOX accumulation: the presence and the activity of mitochondrial efflux pumps and their relationship with mitochondrial ATP synthesis were analyzed in DOX-resistant (MCF-7doxR) and -sensitive (MCF-7S) breast cancer cells. Mitochondrial accumulation of DOX (autofluorescence) was decreased when ATP was produced, but only in MCF-7doxR. In these DOX-resistant cells, breast cancer resistance protein (BCRP) and multidrug resistance-associated protein (MRP1) were expressed and localized in mitochondria (confocal microscopy and confocal spectral imaging studies). In addition, mitochondrial accumulation of DOX was increased by BCRP and MRP1 inhibitors and, to a lower extent, by the mitochondrial ATP synthase inhibitor, oligomycin, in MCF-7doxR.
CONCLUSIONS: Both BCRP and MRP1 were localized in mitochondria and participated to the reduction of mitochondrial accumulation of DOX in MCF-7doxR. This process was partly dependent of mitochondrial ATP synthesis. GENERAL SIGNIFICANCE: The present study provides novel insights in the involvement of mitochondria in the underlying mechanisms of DOX-resistance in breast cancer cells.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast cancer resistance protein; Chemoresistance; Mitochondrial ATP synthesis; Multidrug resistance-associated protein

Mesh:

Substances:

Year:  2017        PMID: 28214549     DOI: 10.1016/j.bbagen.2017.02.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  14 in total

1.  MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor.

Authors:  Jiaqi Li; Jing Zhao; Huan Wang; Xiaohan Li; Aixia Liu; Qin Qin; Boan Li
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

2.  Nanoparticle delivery of a pH-sensitive prodrug of doxorubicin and a mitochondrial targeting VES-H8R8 synergistically kill multi-drug resistant breast cancer cells.

Authors:  Petro Czupiel; Vianney Delplace; Molly Shoichet
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

3.  Synergistic Activity of Fluoroquinolones Combining with Artesunate Against Multidrug-Resistant Escherichia coli.

Authors:  SiMin Wei; YueFei Yang; Wei Tian; MingJiang Liu; ShaoJie Yin; JinGui Li
Journal:  Microb Drug Resist       Date:  2019-11-22       Impact factor: 3.431

Review 4.  Strategies for the enhanced intracellular delivery of nanomaterials.

Authors:  Cláudia Azevedo; Maria Helena Macedo; Bruno Sarmento
Journal:  Drug Discov Today       Date:  2017-09-15       Impact factor: 7.851

5.  Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.

Authors:  Mariam A Fouad; Mohamed M Sayed-Ahmed; Etimad A Huwait; Hafez F Hafez; Abdel-Moneim M Osman
Journal:  BMC Pharmacol Toxicol       Date:  2021-01-28       Impact factor: 2.483

Review 6.  Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.

Authors:  Paras Famta; Saurabh Shah; Essha Chatterjee; Hoshiyar Singh; Biswajit Dey; Santosh Kumar Guru; Shashi Bala Singh; Saurabh Srivastava
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-06

Review 7.  Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

Authors:  Chien Ing Yeo; Kah Kooi Ooi; Edward R T Tiekink
Journal:  Molecules       Date:  2018-06-11       Impact factor: 4.411

8.  Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.

Authors:  Hui Yu; Jia-Mi Li; Kai Deng; Wei Zhou; Cai-Xia Wang; Qian Wang; Kun-Heng Li; Hong-Yang Zhao; Shi-Wen Huang
Journal:  Theranostics       Date:  2019-09-21       Impact factor: 11.556

9.  Self-Propelling Targeted Magneto-Nanobots for Deep Tumor Penetration and pH-Responsive Intracellular Drug Delivery.

Authors:  Saloni S Andhari; Ravindra D Wavhale; Kshama D Dhobale; Bhausaheb V Tawade; Govind P Chate; Yuvraj N Patil; Jayant J Khandare; Shashwat S Banerjee
Journal:  Sci Rep       Date:  2020-03-13       Impact factor: 4.379

Review 10.  Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components.

Authors:  Entaz Bahar; Sun-Young Han; Ji-Ye Kim; Hyonok Yoon
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.